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Abstract
Purpose Graves’ disease can induce alterations of the
psychosocial well-being that negatively influence the
overall well-being of patients. Among the current treat-
ments, surgery has limited indications, and its impact on
the health-related quality of life has not been well clarified.
The aim of this study was to assess the impact of surgery
on the quality of life.
Methods Fifty-seven patients who underwent total thy-
roidectomy for Graves’ disease in our surgical unit
between April 2002 and December 2009 were administered
a questionnaire concerning four issues: organic alterations
and clinical manifestations, neurovegetative system dis-
turbances, impairment of daily activities, psychosocial
problems. Patients were retrospectively questioned after
thyroidectomy about the presence of these symptoms in
both the pre and postoperative periods.
Results There was a significant improvement after sur-
gery in all four areas. Organic manifestations and psy-
chosocial problems had higher average improvements, as
did some aspects of the neurovegetative system and diffi-
culties in undertaking daily activities. There were no
reports of a worsening of symptoms.
Conclusions Surgery resolved the hyperthyroidism in
100 % of cases, and was associated with a quality of life
improvement of about 70 % in the patients. Surgery can
therefore provide an immediate and effective resolution of
Graves’ disease, with benefits in health-related quality of
life.
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Introduction
Graves’ disease (GD) is an autoimmune thyroid disorder
characterized by the presence of immunoglobulins in the
blood that stimulate the thyroid and bind to thyrotropin
receptors, leading to hyperfunction of the gland and con-
sequent excessive secretion of thyroid hormones. GD is the
most common cause of hyperthyroidism. The incidence of
GD is estimated at 5 per 1,000 per year, with a female-
to-male ratio of 7:1 [1]. Patients with untreated GD suffer
from a wide range of symptoms, and a substantial portion
of them experience limitations in their usual activities,
perceive their general health as impaired, and experience
social and emotional deterioration [2]. Thus, the impact of
GD on the overall well-being of patients cannot be
neglected, and some studies have shown that patients with
the disease can have a diminished health-related quality of
life (HRQOL) [2, 3]. As a result, the importance of taking
the HRQOL into consideration when evaluating thyroid
patients has become increasingly recognized as one of the
main goals of the various disease treatments [4].
To date, pharmacological therapy (methimazole, pro-
pylthiouracil, carbimazole) is the principal strategy used in
many European countries (77 %) and in Japan (88 %) [5],
while radioactive iodine therapy is usually recom-
mended in North America (70 %) [6, 7]. Surgical therapy
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undoubtedly leads to an immediate (100 % of cases [6])
and permanent (92 % of cases [8]) resolution of hyper-
thyroidism, and reduces the possible progression of oph-
thalmopathy, resulting in a rapid clinical improvement. It
also minimizes the risk of malignancy in patients with
concomitant GD and thyroid nodules [9].
Despite these benefits, patients with GD are rarely
indicated for surgery, and the impact of surgery on the
HRQOL has not yet been well documented [10]. In fact,
the HRQOL has been studied principally in the setting of
orbitopathy [11, 12], where it seems that a worsening
HRQOL is related to the grade of ophthalmopathy [12].
However, no studies have so far focused on the impact of
surgery on the subsequent HRQOL in GD patients.
The aim of our study was therefore to assess the effec-
tiveness of surgical therapy on one of the most important
aspects of the disease, namely, the quality of life of indi-
vidual patients.
Materials and methods
This study was retrospectively carried out on 57 of 62
patients who had undergone total thyroidectomy for
Graves’ disease (diagnosis confirmed by histology) at the
Operative Surgical Unit of P. Giaccone University Hospi-
tal, in Palermo, Italy from April 2002 to December 2009.
In order to avoid an important bias, we recruited patients
with no or mild orbitopathy, excluding those who presented
proptosis, and those with preoperative hyperparathyroid-
ism. In addition, we excluded five patients: three because
of an incidental coexistent papillary carcinoma on final
pathology, and two who were untraceable during active
recruitment. The diagnosis of GD was made by assessment
of the clinical features, an antibody analysis, and ultra-
sound scanning. Our indications for surgery were similar to
the generally accepted indications: large goiters with
compressive symptoms (19/57 in our group); intolerance or
failure of medical therapy (23/57); recurrent hyperthy-
roidism (28/57); co-existence of nodules with ultrasound
features and/or biopsy suspicious for malignancy (3/60, all
excluded from the study because of confirmed malignan-
cies); history of irradiation to the head and neck (1/57);
patients preferring rapid resolution of their discomfort
(5/57).
The patients had been operated on by the same surgical
team (two of three expert surgeons, G.G., G.S. and N.C.P.,
treated each patient) and were followed up periodically at
our Endocrine Surgery Unit. The postoperative hospital
stay after the operation was 1 day in 50 cases, and 2 days
in seven cases, for an average of 1.1 days. From April to
June 2008 and from February to June 2010, a standardized
questionnaire was administered retrospectively to each
patient by a single individual (a person on the surgical team
already known to the patient). The questionnaire was
administered between 6 months and 6 years after surgery,
with a median of 3 years (range 5–49 months). After
obtaining informed consent from each patient, and official
approval from the Internal Review Board of our hospital,
each interview with the questionnaire was conducted dur-
ing a mean time of 15 min. The study protocol conformed
to the ethical guidelines of the 1975 Declaration of Hel-
sinki and was in accordance with Italian regulations. Ethics
committee approval was not required for this study.
To compare the results obtained in terms of quality of
life and to provide a control group, we administered the
same questionnaire from February to June 2010 to a group
of patients recruited from the Endocrine Surgery Unit of
our hospital who had received medical therapy with
methimazole, each of them for a different time period, with
a mean of 30 months (range 12–48 months). There were 25
patients in the control group, none of whom had undergone
surgery: four males (16 %) and 21 females (84 %) with
mean age of 46 years. The mean thyroid volume was
36.9 ml, and the patients had been affected with GD for a
period ranging from 2 to 7 years. This control group was
necessarily smaller because the patients were matched for
the same features as the surgery group (age, gender,
occupation and thyroid volume).
Questionnaire
Based on the most frequently observed symptoms and
questionnaires found in the international literature (Medi-
cal Outcomes Study-24 questionnaire [13]; Short Form-36
questionnaire [14]; EuroQol VAS Questionnaire [15];
National Eye Institute Visual Function Questionnaire [16];
Profile of Mood States [17]; Graves’ ophthalmopathy
Quality of Life Questionnaire-GOQOL [18]), we devel-
oped a questionnaire to measure the HRQOL in patients
who had undergone total thyroidectomy for GD. Many of
the questions included in our questionnaire were derived
from these previously cited studies and were thus consid-
ered to be validated. The questionnaire was pilot tested on
10 patients to evaluate its repeatability (test/retest reli-
ability), readability, and comprehension of each item. The
final version of the questionnaire included 36 items orga-
nized into 5 different sections:
1. Private data and social-demographic information
(n = 4):
• age
• gender
• marital status
• occupation
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2. Organic and clinical manifestations (n = 6):
• deterioration of visual faculties (conjunctivitis,
diplopia, lack of ocular convergence, decreased
visual acuity, blurred vision, chemosis, irritation,
tearing, spontaneous retro-bulbar pain and pain
with ocular movement, photophobia, ocular foreign
body sensation)
• objective changes in the face and body (proptosis,
lagophthalmos, eyelid retraction or extension,
ocular erythema, swelling of the lachrymal carun-
cle, edema of the face, hands, feet and periorbital
region, weight changes, fragility of the skin, nails
and hair, change in voice, enlarged tongue,
gynecomastia)
• cardiovascular problems (blood pressure and heart
rate alteration, palpitations, fibrillation)
• gastrointestinal problems (difficulty swallowing,
sensation of postprandial fullness, diarrhea or
constipation, vomiting, nausea)
• respiratory disorders (dyspnea, chest pain, pharyn-
gitis, bronchitis)
• skeletal and muscular alterations (hand tremors,
fatigue, pain, adynamia, asthenia).
All the items were measured on a three-point scale,
categorized as 0 (‘‘none’’), 1 (‘‘some’’), and 2
(‘‘many’’). For each patient, a sub-score was created
by averaging the scores for the six items.
3. Aspects of the neurovegetative system and other
general alterations related or not to thyroid disorders
(n = 6):
• disorders of the peripheral nervous system (heat or
cold intolerance, dizziness, altered sense of hear-
ing, smell, taste)
• alteration of physiological sweating
• increased or decreased appetite
• menstrual disturbances
• sexual problems (impotence and/or decreased
libido)
• headache
All the items were measured on a three-point scale,
categorized as 0 (‘‘none’’), 1 (‘‘some’’), and 2
(‘‘many’’). For each patient, a sub-score was created
by averaging the scores of the six items.
4. Daily activities (n = 7):
• driving a car
• reading a newspaper
• working
• performing household chores (cooking, moving
indoors or outdoors)
• watching TV
• engaging in a hobby
• walking or cycling or using public transport.
All the items were measured on a three-point scale,
categorized as 0 (‘‘no limitations’’), 1 (‘‘moderate
limitations’’), and 2 (‘‘severe limitations’’). For
each patient, a sub-score was created by calculating
the average of the scores for the seven items.
5. Psychological and social problems (n = 12):
• emotional lability
• sleep disorders (insomnia)
• hyperactivity, anxiety or nervousness
• depression
• loss of self confidence
• stress
• decreased attention and/or memory span
• decreased capacity for planning and/or solving
complex problems
• hallucinations
• social isolation (difficulty in making friends, feel-
ing continuously observed, appearing less fre-
quently in photographs)
• using camouflage to change self appearance
• observing any change in attitude on the part of
others towards the patient (unpleasant answers, a
lack of availability).
All the items were measured on a three-point scale,
categorized as 0 (‘‘no limitations’’), 1 (‘‘moderate
limitations’’) and 2 (‘‘severe limitations’’). For
each patient, a sub-score was created by averaging
the scores of the 12 items.
6. Scar quality (n = 1) as perceived by the patients and
assessed as ‘‘excellent,’’ ‘‘good,’’ or ‘‘poor.’’
Items in sections 2–5 of the questionnaire investigated the
HRQOL, both as retrospectively recalled by patients about
their status before surgery and as the HRQOL at the time of
the interview. Lower HRQOL scores indicated better health.
The thyroid volume was obtained from the patients’
medical records, then by ultrasound, and subsequently by
the final pathological examination. We evaluated the con-
ditions of hormone compensation (dose of thyroid hor-
mones, parathyroid hormone (PTH), and values of TSH
receptor antibodies, or TRAb) (Table 4). All patients were
confirmed to be in a condition of hyperthyroidism when the
surgical option was proposed, and underwent total thy-
roidectomy in a state of clinical-biological euthyroidism
after 1–2 months of medical therapy (methimazole). In
addition, since the patients with preoperative hyperpara-
thyroidism were excluded and there was no alteration in
either the preoperative (hyperparathyroidism) or postoper-
ative (iatrogenic hypoparathyroidism) levels, it was not
necessary to investigate vitamin D values.
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We usually follow our patients for up to 12–18 months
after surgery through clinical, laboratory (dose of serum
calcium levels, thyroid hormone levels and TRAb) and
instrumental (ultrasound scanning) evaluations. We per-
formed examinations with a fiberoptic laryngoscope in
cases with vocal cord alterations. The median interval
between symptom onset and the surgery for these patients
was 12 months (range 4–48 months).
Statistical analysis
The questionnaire responses were entered into an elec-
tronic worksheet (Microsoft Excel). Absolute and relative
frequencies were calculated for qualitative variables, while
quantitative variables were summarized as the mean ±
standard deviation or medians (range). The means and
95 % confidence intervals (95 % CIs) were also
calculated.
Quantitative variables were compared with the paired or
unpaired Student’s t test, ANOVA or the Mann–Whitney
U test, as appropriate. Statistical significance for all anal-
yses was established as a two-tailed p value of 0.05. All the
data were analyzed using the R statistical software package
[19].
Results
The characteristics of the 57 patients, comprising nine
males (16 %) and 48 females (84 %), with a mean age of
47.7 ± 13.7 years, are shown in Table 1. Of the study
participants, 37 % were employed, in a variety of occu-
pational sectors. The mean thyroid volume was
34.7 ± 15 ml.
As shown in Fig. 1, before surgery, organic manifesta-
tions were the most significant problems, with an average
score of 1.1. The psychosocial and neurovegetative
problems were perceived to be moderately limiting (aver-
age score per item = 0.63), whereas difficulties in daily
activities were considered to be not very limiting (average
score per item = 0.22). Among the different symptoms/
problems, those associated with severe limitations were
cardiovascular alterations (in 37 patients, 65 %), skeletal
and muscular alterations (in 35 patients, 61 %), physio-
logical sweating (in 23 patients, 40 %), and objective
changes in the face and body (in 22 patients, 39 %).
All the investigated symptoms/signs had a significant
improvement 3–6 months after surgery. The organic/clin-
ical manifestations and psychosocial problems had higher
average improvements than the other issues examined
(from 1.1 to 0.28, and from 0.63 to 0.19, respectively;
p \ 0.001 in both cases). Neurovegetative system prob-
lems and difficulties in daily activities had lower, but still
significant, improvements (from 0.63 to 0.20, and from
0.22 to 0.06, respectively; p \ 0.001 in both cases). Based
on the total score of organic alterations and clinical man-
ifestations, neurovegetative system disturbances, limita-
tions of daily activities and psychosocial problems, there
was a shift from 0.63 before surgery to 0.18 after surgery
(p \ 0.001).
The ten main alterations/problems affecting the HRQOL
before surgery are summarized in Table 2. Organic prob-
lems and clinical manifestations (cardiovascular disorders,
skeletal and muscular alterations, objective changes in the
face and body) were the three items with the highest scores.
These ten items all had significant improvements following
surgery, ranging from 61 to 86 % improvement.
Considering 31 items, after excluding the 4 questions
included in part 1 and the sole item in part 6, the social
isolation, limited working capacity and cardiovascular
alterations were those registering the highest improvements
after surgery (93, 90 and 86 %, respectively) (data not
shown).
None of the variables considered in this study (age,
gender, occupation and thyroid volume) were significantly
related to a higher improvement in the health-related
quality of life (Table 3). The individual assessment of the
final wound was excellent for 41 patients (72 %), good for
16 (28 %) and insufficient to none (0 %).
Regarding hormonal compensation, no patient had a
recurrence of persistent hyperthyroidism; two patients had
subclinical hypothyroidism despite replacement therapy,
while none of the patients had clinical hypothyroidism.
Fifty-six of the 57 patients (98 %) had no long-term
complications or permanent hypocalcemia 6 months after
surgery. None of the patients took long-term calcium
replacement therapy (after 6 months); in all patients there
was a gradual decrease in serum TRAb levels and no sig-
nificant differences between the pre and postoperative PTH
values, which were normal (Table 4). However, it should
Table 1 Patient characteristics
n = 57
Age in years, mean (SD) 47.7 (13.7)
Gender, n (%)
Male 9 (15.8)
Female 48 (84.2)
Occupation, n (%)
Unemployed/student 10 (17.6)
Housewife 14 (24.5)
Employed, different sectors 21 (36.8)
Retired 12 (21.1)
Thyroid volume in ml, mean (SD) 34.7 (15)
n total number of patients
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be borne in mind that the general consensus in the literature
is that normalization of the autoimmune abnormality
comes much later, after at least 18 months [20, 21]. One
patient (2 %) in our study had transient unilateral vocal
cord palsy detected by the fiberoptic laryngoscope, but
without evident impairment of the voice.
With regard to the control group, in addition to the well-
known side effects and recurrences following medical
therapy [22, 23], the most frequent problems that persisted
despite anti-thyroid drug treatment concerned clinical
manifestations (gastrointestinal, cardiovascular and mus-
cular alterations), and also alterations in physical appear-
ance, neurovegetative and psychological systems (anxiety,
insomnia, depression and stress) and social disorders. Some
improvement was observed in body weight and hormonal
values at the beginning of therapy; although worsened
ocular pressures, exophthalmos and migraine were also
observed (final results summarized in Table 5). Finally, the
patients who underwent surgery had lower HQOL scores
than patients (n = 25) who were treated with anti-thyroid
drugs (p \ 0.001) (Table 5). Therefore, compared with the
control group, the patients who underwent surgery had a
better QOL than those that received prolonged medical
therapy.
Discussion
Graves’ disease is the most common cause of hyperthy-
roidism (60–80 %) [5] and thyrotoxicosis. It affects
Fig. 1 The health-related
quality of life (organic/clinical,
psychosocial, neurovegetative,
daily activities and total scores)
in patients before and
3–6 months after surgery (lower
scores indicate better health)
Table 2 The top ten alterations/problems affecting the health-
related quality of life in patients with graves’ disease before surgery,
and 3–6 months after surgery
Alteration/problem Category Score before
surgery
Score after
surgery
Cardiovascular disorders CM 1.61 0.23
Skeletal and muscular
alterations
CM 1.46 0.37
Objective changes in the
face and body
CM 1.18 0.32
Alteration of
physiological sweating
NS 1.11 0.33
Emotional lability PSS 1.11 0.33
Hyperactivity, anxiety or
nervousness
PSS 1.07 0.30
Gastrointestinal disorders CM 1.03 0.40
Sleep disorders PSS 0.98 0.30
Depression PSS 0.98 0.24
Increased or decreased
appetite
NS 0.89 0.21
CM clinical manifestations, NS aspects of neurovegetative system,
PSS psychological and social problems
Table 3 Average improvement in the health-related quality of life in
patients, stratified by gender, age, occupation and thyroid volume
Average improvement
in health-related quality
of life ± SD
p value
Gender
Male 11.2 ± 4.3 0.18*
Female 14.5 ± 7.1
Age (years)
\35 16.7 ± 8.3 0.48**
35–49 12.7 ± 5.7
50–64 13.8 ± 6.5
[65 13.6 ± 8
Occupation
Unemployed/student 15.1 ± 8.3 0.96**
Housewife 13.9 ± 6.1
Employed, different sectors 13.7 ± 7
Retired 13.8 ± 7
Thyroid volume (ml)
\30 14.2 ± 7.7 0.94**
30–39 13.6 ± 7.4
[39 14.3 ± 4.7
* Unpaired Student’s t test
** ANOVA
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females 10 times more frequently than males, and overall,
generally affects those between the ages of 40 and
60 years, but can also manifest in females of childbearing
age [24]. The reported epidemiological features of Graves’
disease were well represented in our study sample, allow-
ing us to hypothesize a reasonable generalizability of our
results.
Graves’ disease is clinically characterized by a sym-
metrical goiter, hyperthyroidism and an infiltrative oph-
thalmopathy often associated with a dermopathy.
Ophthalmopathy is the most common extrathyroidal man-
ifestation of Graves’ disease (50 % of cases) [25], and is a
greatly limiting condition in patients. GD is also often
associated with changes in physical appearance, especially
in the eyes and face, which become disfigured, and alter-
ations of the mental state, such as depression, anxiety,
mania, cognitive dysfunction [26], and is sometimes
associated with psychiatric and psychosocial disorders
[27], such as confusion, tension, anger, inertia, hostility,
inability to work, uncertainty of the future, unhappiness,
panic episodes and isolation. All these factors may also
weigh heavily on the psychological well-being of these
patients by interfering with their daily activities [27]. Our
findings confirm that, before surgery, Graves’ disease
patients have a diminished HRQOL, which involves all the
aspects investigated in our study, in particular, as a con-
sequence of the organic and clinical manifestations of the
disease. Following surgery, the HRQOL still remained
impaired, although a general improvement was evident,
with improvements in sub-scores ranging from 69 % (for
aspects related to the neurovegetative system) to 75 %
(relating to organic manifestations). Overall, surgery was
associated with an increase of about 70 % in the HRQOL.
Although many of our questions were culled from the
literature, our questionnaire was largely original and
designed to be applicable to, and valid for, our patient
population. As a result, our findings may not be fully
comparable with those of other studies. However, the lack
of a questionnaire that assesses the psychological status, as
well as the general, clinical and psychosocial aspects of
GD in all its complexity, as well as the response to medical
and/or surgical treatment, is acknowledged in the interna-
tional literature [2, 18, 28].
Surprisingly, our results showed that none of the patient
characteristics were significantly associated with a higher
HRQOL impairment after surgery. This finding suggests
that surgical treatment achieves similar HRQOL benefits
regardless of the patient age, gender and thyroid volume, so
that even patients of older age or with a high thyroid vol-
ume should be considered likely to benefit from such
therapy.
Finally, this study has important limitations that need to
be kept in mind when interpreting the results, such as the
retrospective administration and evaluation of the ques-
tionnaire, the subjectivity of the estimation of visual ability
and cosmetic results, the limited sample size; use of
anamnestic findings for some aspects (possible recall bias),
the treatments performed by a single surgical team at a
single center, and the long-time interval between surgery
and the interview for some patients. We are well aware that
it may have been better to administer the questionnaire
preoperatively and then again after a defined period of time
following thyroidectomy, but a prospective study would
require a high number of patients, which our unit, per-
forming an average number of thyroidectomies annually,
would not be able to recruit in a reasonable time interval.
We performed a longitudinal study with a retrospective
approach to preliminarily assess the role of surgery in
improving the patient QoL. This study methodology is
certainly not new, although some have found that
‘‘a method for measuring change in QoL incorporating a
retrospective baseline-measurement showed strongest
associations with change in clinical indicators of health
status, suggesting a more valid measurement of change in
Table 4 The median serum antibody values during the pre and
postoperative periods (12 months after surgery)
Antibodies Before surgery After surgery
(12 months)
p value*
TRAb (IU/L)
Median (range)
3.2 (0.3–13.3) 1.4 (0.2–8.0) \0.001
TPO Ab (IU/mL)
Median (range)
43.8 (6.7–140.0) 40.0 (6.0–215.0) \0.01
TG Ab (IU/mL)
Median (range)
83.0 (11.0–139.0) 78.0 (11.0–30.0) \0.001
PTH (pg/mL)
Mean (standard
deviation)
45.8 (31–65) 47.6 (35–70) 0.17
TRAb TSH-receptor antibodies, TPO Ab thyroid peroxidase antibod-
ies, TG Ab thyroglobulin antibodies, PTH parathyroid hormone
* Paired Student’s t test
Table 5 Average improvement in the health-related quality of life in
patients who underwent surgery and in patients treated with anti-
thyroid drugs
Alteration/
problem
Average score ± SD p value*
Patients who
underwent
surgery
Patients treated with
anti-thyroid drugs
Organic/clinical 0.28 ± 0.27 0.92 ± 0.50 \0.001
Psychosocial 0.20 ± 0.20 0.63 ± 0.35 \0.0001
Neurovegetative 0.20 ± 0.16 0.58 ± 0.35 \0.001
Daily activities 0.06 ± 0.13 0.11 ± 0.32 0.26
Total 0.19 ± 0.14 0.56 ± 0.24 \0.001
* Unpaired Student’s t test
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QoL than a conventional prospective method’’ [29]. This
retrospective approach is associated with the theory of
‘‘response shift,’’ which revolves on the notion that
patients’ perceptions of, and expectations for, QoL shift
over time, and that a retrospective analysis takes this shift
into account more fully than does a prospective approach.
The other school of thought, the ‘‘implicit theory of
change,’’ hinges on the idea that patients assume an
implicit change in their present status and then try to gather
impressions of a previous status based on their present
state, thus introducing an important bias. The ‘‘implicit
change’’ theorists stress the idea that only actual states of
health can be measured, and that this can only be done
prospectively. The ‘‘response shift’’ theorists claim that a
prospective approach compromises any modification of
personal expectation and perception on the patient’s part. It
is important to underscore the fact that the theory of
‘‘response shift’’ was prompted largely by studies that
found patients’ positive perceptions of their HRQOL
objectively at odds with their poor health status. Although
there is much debate over the most appropriate study
design for measuring HRQOL, there have been no com-
pelling studies comparing the two. We believe, however,
that while a retrospective design is not free of bias, it does
accurately reflect the patient’s current perception of their
HRQOL, which, in a clinical setting, is of central impor-
tance. Had we not discovered that all of the patients
operated on for GD in our study had a 100 % surgical
success rate, and had we included patients in the study in
whom surgery had failed, the relevance of a ‘‘response
shift’’ bias would have been stronger. However, all of the
patients in our study had successful surgery, thus guaran-
teeing a certain homogeneity without having to exclude
any patients with unsuccessful surgery. We also believe
that our findings are important in light of the fact that
surgery is still not often recommended as a first approach in
GD patients.
Despite these potential limitations of our study, we
observed that surgical therapy resolved the hyperthyroid
condition in 100 % of cases, leading to an improvement in
the HRQOL of patients in almost all cases examined,
especially with regard to the organic/clinical and psycho-
social problems, with no deterioration recorded in any
patient.
Conclusions
Surgery should be proposed as an immediate and com-
pletely effective solution for GD, especially when com-
pared with prolonged medical therapy, because it can
provide a demonstrable improvement in the HRQOL of
patients. We think it is important to stress that some
preoperative symptoms, such as social isolation, limited
working capacity and cardiovascular alterations, seem to
resolve better than other symptoms with surgery.
Although this was a retrospective study, we think that it
may offer important and useful information for the
international scientific community, and perhaps contrib-
ute to enriching and promoting research in this field,
although further studies will have to be carried out to
confirm our findings.
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